Literature DB >> 22675174

Molecular profiling reveals low- and high-grade forms of primary melanoma.

Katja Harbst1, Johan Staaf, Martin Lauss, Anna Karlsson, Anna Måsbäck, Iva Johansson, Pär-Ola Bendahl, Johan Vallon-Christersson, Therese Törngren, Henrik Ekedahl, Jürgen Geisler, Mattias Höglund, Markus Höglund, Markus Ringnér, Mattias Ringnér, Lotta Lundgren, Karin Jirström, Håkan Olsson, Christian Ingvar, Åke Borg, Hensin Tsao, Göran Jönsson.   

Abstract

PURPOSE: For primary melanomas, tumor thickness, mitotic rate, and ulceration are well-laid cornerstones of prognostication. However, a molecular exposition of melanoma aggressiveness is critically missing. We recently uncovered a four-class structure in metastatic melanoma, which predicts outcome and informs biology. This raises the possibility that a molecular structure exists even in the early stages of melanoma and that molecular determinants could underlie histophenotype and eventual patient outcome. EXPERIMENTAL
DESIGN: We subjected 223 archival primary melanomas to a horizontally integrated analysis of RNA expression, oncogenic mutations at 238 lesions, histomorphometry, and survival data.
RESULTS: Our previously described four-class structure that was elucidated in metastatic lesions was evident within the expression space of primary melanomas. Because these subclasses converged into two larger prognostic and phenotypic groups, we used the metastatic lesions to develop a binary subtype-based signature capable of distinguishing between "high" and "low" grade forms of the disease. The two-grade signature was subsequently applied to the primary melanomas. Compared with low-grade tumors, high-grade primary melanomas were significantly associated with increased tumor thickness, mitotic rate, ulceration (all P < 0.01), and poorer relapse-free (HR = 4.94; 95% CI, 2.84-8.59), and overall (HR = 3.66; 95% CI, 2.40-5.58) survival. High-grade melanomas exhibited elevated levels of proliferation and BRCA1/DNA damage signaling genes, whereas low-grade lesions harbored higher expression of immune genes. Importantly, the molecular-grade signature was validated in two external gene expression data sets.
CONCLUSIONS: We provide evidence for a molecular organization within melanomas, which is preserved across all stages of disease.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22675174      PMCID: PMC3467105          DOI: 10.1158/1078-0432.CCR-12-0343

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  22 in total

Review 1.  DNA microarray analyses of melanoma gene expression: a decade in the mines.

Authors:  Keith S Hoek
Journal:  Pigment Cell Res       Date:  2007-12

2.  Distinct sets of genetic alterations in melanoma.

Authors:  John A Curtin; Jane Fridlyand; Toshiro Kageshita; Hetal N Patel; Klaus J Busam; Heinz Kutzner; Kwang-Hyun Cho; Setsuya Aiba; Eva-Bettina Bröcker; Philip E LeBoit; Dan Pinkel; Boris C Bastian
Journal:  N Engl J Med       Date:  2005-11-17       Impact factor: 91.245

3.  Clinical outcome and pathological features associated with NRAS mutation in cutaneous melanoma.

Authors:  Bianca Devitt; Wendy Liu; Renato Salemi; Rory Wolfe; John Kelly; Chin-Yuan Tzen; Alexander Dobrovic; Grant McArthur
Journal:  Pigment Cell Melanoma Res       Date:  2011-06-22       Impact factor: 4.693

4.  Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma.

Authors:  Levi A Garraway; Hans R Widlund; Mark A Rubin; Gad Getz; Aaron J Berger; Sridhar Ramaswamy; Rameen Beroukhim; Danny A Milner; Scott R Granter; Jinyan Du; Charles Lee; Stephan N Wagner; Cheng Li; Todd R Golub; David L Rimm; Matthew L Meyerson; David E Fisher; William R Sellers
Journal:  Nature       Date:  2005-07-07       Impact factor: 49.962

5.  Gene expression profiling of primary cutaneous melanoma and clinical outcome.

Authors:  Véronique Winnepenninckx; Vladimir Lazar; Stefan Michiels; Philippe Dessen; Marguerite Stas; Soledad R Alonso; Marie-Françoise Avril; Pablo L Ortiz Romero; Thomas Robert; Ovidiu Balacescu; Alexander M M Eggermont; Gilbert Lenoir; Alain Sarasin; Thomas Tursz; Joost J van den Oord; Alain Spatz
Journal:  J Natl Cancer Inst       Date:  2006-04-05       Impact factor: 13.506

6.  Tumor-infiltrating lymphocytes predict sentinel lymph node positivity in patients with cutaneous melanoma.

Authors:  Rebecca C Taylor; Ami Patel; Katherine S Panageas; Klaus J Busam; Mary S Brady
Journal:  J Clin Oncol       Date:  2007-03-01       Impact factor: 44.544

7.  Model predicting survival in stage I melanoma based on tumor progression.

Authors:  W H Clark; D E Elder; D Guerry; L E Braitman; B J Trock; D Schultz; M Synnestvedt; A C Halpern
Journal:  J Natl Cancer Inst       Date:  1989-12-20       Impact factor: 13.506

8.  High expression of DNA repair pathways is associated with metastasis in melanoma patients.

Authors:  A Kauffmann; F Rosselli; V Lazar; V Winnepenninckx; A Mansuet-Lupo; P Dessen; J J van den Oord; A Spatz; A Sarasin
Journal:  Oncogene       Date:  2007-09-24       Impact factor: 9.867

Review 9.  Cutaneous melanoma: fishing with chips.

Authors:  Sandeep Nambiar; Alireza Mirmohammadsadegh; Ulrich R Hengge
Journal:  Curr Mol Med       Date:  2008-05       Impact factor: 2.222

10.  Deregulated Akt3 activity promotes development of malignant melanoma.

Authors:  Jill M Stahl; Arati Sharma; Mitchell Cheung; Melissa Zimmerman; Jin Q Cheng; Marcus W Bosenberg; Mark Kester; Lakshman Sandirasegarane; Gavin P Robertson
Journal:  Cancer Res       Date:  2004-10-01       Impact factor: 12.701

View more
  51 in total

1.  High MITF Expression Is Associated with Super-Enhancers and Suppressed by CDK7 Inhibition in Melanoma.

Authors:  Philip Eliades; Brian J Abraham; Zhenyu Ji; David M Miller; Camilla L Christensen; Nicholas Kwiatkowski; Raj Kumar; Ching Ni Njauw; Michael Taylor; Benchun Miao; Tinghu Zhang; Kwok-Kin Wong; Nathanael S Gray; Richard A Young; Hensin Tsao
Journal:  J Invest Dermatol       Date:  2018-02-08       Impact factor: 8.551

2.  Prognostic molecular testing in melanoma: ready for prime time?

Authors:  Jennifer Keller; Laurence P Diggs; Eddy C Hsueh
Journal:  Melanoma Manag       Date:  2017-07-31

3.  Advances in molecular profiling of malignant melanoma: ready for clinical practice?

Authors:  Göran Jönsson
Journal:  Melanoma Manag       Date:  2014-09-05

Review 4.  Predicting the outcome of melanoma: can we tell the future of a patient's melanoma?

Authors:  Oriol Yélamos; Pedram Gerami
Journal:  Melanoma Manag       Date:  2015-08-10

Review 5.  Molecular pathology of cutaneous melanoma.

Authors:  Léon C van Kempen; Margaret Redpath; Caroline Robert; Alan Spatz
Journal:  Melanoma Manag       Date:  2014-12-04

6.  Mutational and putative neoantigen load predict clinical benefit of adoptive T cell therapy in melanoma.

Authors:  Martin Lauss; Marco Donia; Katja Harbst; Rikke Andersen; Shamik Mitra; Frida Rosengren; Maryem Salim; Johan Vallon-Christersson; Therese Törngren; Anders Kvist; Markus Ringnér; Inge Marie Svane; Göran Jönsson
Journal:  Nat Commun       Date:  2017-11-23       Impact factor: 14.919

Review 7.  Melanoma: clinical features and genomic insights.

Authors:  Elena B Hawryluk; Hensin Tsao
Journal:  Cold Spring Harb Perspect Med       Date:  2014-09-02       Impact factor: 6.915

8.  Genome-Wide DNA Methylation Analysis in Melanoma Reveals the Importance of CpG Methylation in MITF Regulation.

Authors:  Martin Lauss; Rizwan Haq; Helena Cirenajwis; Bengt Phung; Katja Harbst; Johan Staaf; Frida Rosengren; Karolina Holm; Mattias Aine; Karin Jirström; Åke Borg; Christian Busch; Jürgen Geisler; Per E Lønning; Markus Ringnér; Jillian Howlin; David E Fisher; Göran Jönsson
Journal:  J Invest Dermatol       Date:  2015-02-23       Impact factor: 8.551

9.  Biological Validation of RNA Sequencing Data from Formalin-Fixed Paraffin-Embedded Primary Melanomas.

Authors:  Lawrence N Kwong; Mariana Petaccia De Macedo; Lauren Haydu; Aron Y Joon; Michael T Tetzlaff; Tiffany L Calderone; Chiang-Jun Wu; Man Kam Kwong; Jason Roszik; Kenneth R Hess; Michael A Davies; Alexander J Lazar; Jeffrey E Gershenwald
Journal:  JCO Precis Oncol       Date:  2018-06-14

Review 10.  Revisiting determinants of prognosis in cutaneous melanoma.

Authors:  Sarah A Weiss; Douglas Hanniford; Eva Hernando; Iman Osman
Journal:  Cancer       Date:  2015-08-26       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.